1. Scrip
  2. >>Business
  3. >>Deals

Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play

 
• By Jessica Merrill

Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.

shopping cart
Pfizer is shopping for new clinical-stage assets • Source: Alamy

Pfizer Inc., flush with cash from its COVID-19 vaccine, will buy the clinical-stage immuno-oncology company Trillium Therapeutics Inc. for $2.26bn in an acquisition that will bolster Pfizer's hematology pipeline with two clinical stage compounds targeting a new immune checkpoint, the firms announced 23 August. The acquisition is in line with Pfizer's stated M&A strategy of bringing in mid-stage assets that could drive revenue growth in the 2025-2030 timeframe.

The two lead assets – TTI-622 and TTI-621 – target signal-regulatory protein α (SIRPα -CD47), considered a key immune checkpoint in hematological malignancies. Pfizer believes they could be best-in-class SIRPα fusion proteins with potential as monotherapy and combination drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By Joseph Haas

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By Mandy Jackson

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By Mandy Jackson

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.